- Home
- BUSE vs SNDX Comparison
BUSE vs SNDX Comparison
Compare BUSE & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUSE
- SNDX
- Stock Information
- Founded
- BUSE 1868
- SNDX 2005
- Country
- BUSE United States
- SNDX United States
- Employees
- BUSE N/A
- SNDX N/A
- Industry
- BUSE Major Banks
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- BUSE Finance
- SNDX Health Care
- Exchange
- BUSE Nasdaq
- SNDX Nasdaq
- Market Cap
- BUSE 1.4B
- SNDX 1.2B
- IPO Year
- BUSE N/A
- SNDX 2016
- Fundamental
- Price
- BUSE $24.25
- SNDX $16.38
- Analyst Decision
- BUSE Buy
- SNDX Strong Buy
- Analyst Count
- BUSE 4
- SNDX 10
- Target Price
- BUSE $28.75
- SNDX $36.20
- AVG Volume (30 Days)
- BUSE 355.4K
- SNDX 2.6M
- Earning Date
- BUSE 01-28-2025
- SNDX 03-04-2025
- Dividend Yield
- BUSE 4.12%
- SNDX N/A
- EPS Growth
- BUSE N/A
- SNDX N/A
- EPS
- BUSE 1.98
- SNDX N/A
- Revenue
- BUSE $453,703,000.00
- SNDX $16,000,000.00
- Revenue This Year
- BUSE N/A
- SNDX N/A
- Revenue Next Year
- BUSE $12.48
- SNDX N/A
- P/E Ratio
- BUSE $12.25
- SNDX N/A
- Revenue Growth
- BUSE 3.25
- SNDX N/A
- 52 Week Low
- BUSE $21.59
- SNDX $12.06
- 52 Week High
- BUSE $28.97
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- BUSE 48.86
- SNDX 68.27
- Support Level
- BUSE $24.31
- SNDX $14.53
- Resistance Level
- BUSE $25.31
- SNDX $15.40
- Average True Range (ATR)
- BUSE 0.72
- SNDX 0.70
- MACD
- BUSE 0.01
- SNDX 0.13
- Stochastic Oscillator
- BUSE 39.19
- SNDX 82.93
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.